Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) is the leading clinical-stage messenger RNA medicines Company.
Investment Highlights – Speculative Buy at USD 28.55
Q1 FY21 Financial Highlights (for three months ended 31 March 2021, as of 10 May 2021)
(Source: Company website)
One Year Share Price Chart
(Analysis done by Kalkine Group)
ARCT is making revenue in the form of license fees and collaborative payments received from research & development arrangements with pharmaceutical & biotechnology partners. Moreover, the Company had made accelerated progress towards the advancement of the clinical pipeline. ARCT expects to initiate Phase 3 study of the Covid-19 vaccine ARCT-021 after receiving encouraging interim results from Phase 2 study, indicating favourable safety profile and greater than 90% seroconversion after a single dose. Furthermore, the Company expects to file CTA for Phase 2 multiple-dose study of ARCT-810 (therapeutic candidate for Ornithine Transcarbamylase Deficiency) during Q2 FY21. Currently, it has activated two additional sites in the US for the ongoing Phase 1b study of ARCT-810. The stock made a 52-week low and high of USD 24.87 and USD 129.71, respectively. On the technical chart, the next important support level is at USD 24.87.
Based on the impressive clinical pipeline, encouraging Phase 2 study data of the Covid-19 vaccine candidate ARCT-021, and the various factors discussed above, we have given a "Speculative Buy" stance on Arcturus Therapeutics Holdings Inc at the closing market price of USD 28.55 (as of 26 May 2021).
Retractable Technologies Inc
Retractable Technologies Inc (NYSE: RVP) manufactures, develops and markets safety needle devices. It holds VanishPoint® products which leverage a patented friction ring mechanism to prevent reuse and needlestick injuries.
Investment Rationale – SPECULATIVE BUY at USD 9.08
25 May 2021: RVP announced an amendment to the Technology Investment Agreement with the US government, whereby additional funding of US$27,365,232 will be provided to boost the manufacturing capabilities to meet the US COVID-19 medical countermeasures demands.
Financial Highlights for the quarterly period ended 31 March 2021 (Q1 FY21) (as on 17 May 2021)
(Source: Company Website)
Share Price Chart
(Research done by Kalkine Group)
RVP has delivered strong financial and operating results in Q1 FY21. Despite the pandemic uncertainties, it has witnessed a strong demand for its products. Moreover, its products continued to be distributed nationally and internationally during the pandemic. The Company has increased the workforce and enhanced capabilities to meet the market demand. Further, RVP has substantial financial resources currently to manage its operations and have decent profitability margins to be competitive in the market. The stock made a 52 week High and Low of USD 21.50 and USD 5.11, respectively. On the technical chart, the next important support level is at USD 7.72.
Based on the robust revenue growth, improved financials, enhanced liquidity with additional funding from the US government, favourable market dynamics, we have given a “SPECULATIVE BUY” stance on Retractable Technologies Inc at the closing price of USD 9.08 (as on 26 May 2021).
*Depending upon the risk tolerance, investors may consider unwinding their positions in a respective stock once the estimated target price is reached or if the price closes below the support level (indicative stop-loss price).
*The reference data in this report has been partly sourced from REFINITIV.